Rapid sequence induction and intubation with rocuronium-sugammadex compared with succinylcholine: a randomized trial

Area of Science:

• Anesthesiology
• Critical Care Medicine
• Pharmacology

Background:

• Difficult airways pose risks during rapid sequence induction and intubation (RSII).
• Assessing methods to expedite recovery of spontaneous ventilation post-intubation is crucial.
• Succinylcholine is a common neuromuscular blocking agent, but its prolonged effects can delay ventilation recovery.

Purpose of the Study:

• To compare the time to re-establish spontaneous ventilation after RSII using rocuronium-sugammadex versus succinylcholine.
• To test the hypothesis that rocuronium-sugammadex facilitates a quicker return to spontaneous breathing.

Main Methods:

• A randomized, patient- and observer-blinded trial involving elective surgical patients undergoing general anesthesia.
• Patients received alfentanil, propofol, and either succinylcholine or rocuronium for intubation.
• Sugammadex reversed rocuronium's effects; spontaneous ventilation was defined by respiratory rate and tidal volume.

Main Results:

• The median time to spontaneous ventilation was significantly shorter with rocuronium-sugammadex (216 s) compared to succinylcholine (406 s).
• Recovery of neuromuscular function (T(1) 90%) was also faster with rocuronium-sugammadex (168 s) versus succinylcholine (518 s).
• No significant differences were observed in intubation conditions or time to intubation between the groups.

Conclusions:

• Rocuronium followed by sugammadex reversal enables earlier restoration of spontaneous ventilation post-RSII than succinylcholine.
• This suggests rocuronium-sugammadex is a favorable alternative for expediting recovery in RSII procedures.